Featuring the most promising science Canada’s leading research institutions and health organizations have to offer, the 2021 Early Technology Showcase on February 9 featured high potential research and health science spin-out companies.
Presenting organizations
AGE-WELL, a Canadian centre of excellence, focuses on medtech and digital health solutions for healthy aging.
AGE-WELL Partner companies
BC Cancer, a global leader in precision medicine, will highlight their innovative cell-based therapies for cancer, infectious disease, autoimmunity and regenerative medicine.
BC Cancer Partner company
IRICoR, a Centre of Excellence in Commercialization and Research, is a key national and international player in drug discovery. IRICoR plays an increasingly pivotal role in the development of novel therapies in cancer and related areas.
McMaster University is a leader in health sciences research, and is recognized internationally in biomedical innovation. McMaster will highlight its work in ophthalmology and infectious diseases.
McMaster university Partner company
Stem Cell Network, a national organization supporting regenerative medicine research, is harnessing the power of stem cells and 3D bioprinting of humanized tissue models.
Stem Cell Network partner companies
University Health Network, Canada’s largest research hospital, will highlight its strengths in immunology and cell-based cancer therapies.
university health Network partner companies
University of Ottawa, a leading medical research university, will present a range of projects with focus on smart health and precision medicine.
University of ottawa partner companies
University of Waterloo, Centre for Bioengineering & Biotechnology, will present its capabilities in therapeutics and medtech.
University of Waterloo partner companies
VIDO, a world leader in developing vaccines and technologies against infectious diseases, will present the science of their Phase 1 COVID-19 vaccine.
“The opportunity to engage directly with investors is critical to the development of early-stage health science companies. At the 2020 OBIO Investment Summit, which my company – Inspire Biotherapeutics – attended as a partner company, we were able to get first-hand feedback from investors which enabled us to zero in on the strongest market opportunity for our technology and the greatest likelihood of securing investment. This is invaluable advice and will enable Inspire to succeed faster. I would highly recommend the OBIO Investment Summit to any early-stage company and any research institution that is interested in supporting their spin-out companies.”